In a letter to its own and Bausch & Lomb workers, Valeant said that after the deal closes, it will eliminate between 10 per cent and 15 per cent of positions companywide. That works out to between 1,850 and 2,775 people and is expected to include both Valeant and Bausch & Lomb workers.
The Canadian drugmaker said it will remain based in Quebec, but it will move Bausch & Lomb's Rochester, New York, headquarters to New Jersey. The US company's three businesses will be combined into one unit.
Valeant announced plans in May to by Bausch & Lomb, one of the world's best-known makers of contact lenses, marking a massive expansion of its own smaller ophthalmology business.
The company said at that time that the cash deal will help it capitalize on increasing demand for contact lenses and other products because of aging populations, growing demand in emerging markets and increasing rates of diabetes. Complications of the complex blood sugar disorder can damage the eyes over time.
Valeant expects to achieve at least $800 million in annual cost savings by the end of next year, and said the acquisition will add to its profits immediately.
Investment firm Warburg Pincus, which leads an investment group that owns Bausch & Lomb, will receive $4.5 billion in cash. The remaining $4.2 billion will be used to repay Bausch & Lomb's debt.
US shares of Valeant Pharmaceuticals International Inc. rose 4 cents to $92 in afternoon trading.
black panther party frank martin pink slime eagle cam trayvon martin case affordable care act the line
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.